The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List


Wed, Apr 16, 8:07 AM, Zacks
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
The selloff in the biotech sector continued with overall sentiment remaining bearish.

Tue, Apr 15, 9:30 AM, Zacks
Will Abbott Labs (ABT) Disappoint This Quarter? - Analyst Blog
Abbott Laboratories is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014.

Biogen Idec Inc (BIIB)

Biogen Idec is a global biotechnology company focused on discovering, developing, manufacturing and marketing therapies for the treatment of multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. Co.'s products include: AVONEX (interferon beta-1a), indicated for MS; TYSABRI (natalizumab), indicated for MS and Crohn's disease; FAMPYRA (prolonged-release fampridine tablets), indicated for MS (walking ability); FUMADERM (fumaric acid esters), indicated for psoriasis; and RITUXAN (rituximab), indicated for Non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, and ANCA-associated vasculitis.

Company Name:  Biogen Idec Inc
Sector:  Biotechnology
Number of ETFs Holding BIIB:  80
Total Market Value Held by ETFs:  $3.54B
Total Market Capitalization:  $66.08B
% of Market Cap. Held by ETFs:  5.36%
April 17, 2014    9:36 AM Eastern

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Trade BIIB Now:

Buy (3.37 out of 4)
71st percentile
(ranked higher than approx. 71% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Biogen Idec Inc (BIIB) Page | The Online Investor | | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.